All 1 tracked stories fall under one category: market-trends. PGN-EDO51 is most often covered alongside OmniAb, which appears in 1 of these 1 story. Each story carries 2 original sources on average, compared with 2.8 for the broader beat in this window.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about PGN-EDO51
All 1 tracked stories fall under one category: market-trends. PGN-EDO51 is most often covered alongside OmniAb, which appears in 1 of these 1 story. Each story carries 2 original sources on average, compared with 2.8 for the broader beat in this window. The 5 average consequence score is below the beat benchmark of 5.8 in the same window. We currently track 1 Healthcare story that mention PGN-EDO51, all published on March 5, 2026.
Stories tracked
1
Sources per story
2
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 25 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering PGN-EDO51. Shared-story counts are live from our verified record — not editorial picks.
OmniAb and PepGen reported full-year 2025 results, highlighting a divergence between platform-based stability and clinical-stage volatility. While OmniAb expanded its royalty-bearing portfolio, PepGen faced a significant setback with a partial FDA clinical hold on its Freedom2 trial.